Cancer Research UK-UCL Centre
The Cancer Research UK Centre at UCL is part of a national network of centres funded by Cancer Research UK dedicated to delivering world-leading research, improved patient care and greater local engagement.
- Centre Co-Directors: Professor Daniel Hochhauser and Professor Henning Walczak
- Senior Research Nurse: Miss Emma Hainsworth
- Research Engagement Manager: Miss Jane Schofield
Our vision for the Cancer Research UK - UCL Centre is to foster world-class research into the causes of cancers and why they develop, and use this knowledge to develop new drugs and therapies.
The Centre brings together researchers and clinicians from UCL and its four partner hospital trusts, known as UCL Partners: University College London Hospital NHS Foundation Trust, Great Ormond Street Hospital for Children NHS Trust, the Royal Free Hampstead NHS Trust, and Moorfields Eye Hospital NHS Foundation Trust) as well as the London School of Pharmacy and Cancer Research UK.
The Centre’s focus is on the biology and treatment of blood cancers, sarcomas, brain cancer, ovarian cancer, head and neck cancer and lung cancer. Many of these cancers – particularly lung and brain - are hard to treat successfully and have poor long term survival rates compared to other common cancers. Our vision for cancer research at the Cancer Research UK-UCL Centre is to become world leaders in haemato-oncology, lung cancer and cancers of the nervous system. With our breadth of expertise in tumour immunology, immune-regulation, cancer vaccines, adoptive immunotherapy, T-cell engineering, chimeric antigen receptor (CAR)-engineered lymphocytes and vector design, we can deliver gene, cellular and immune-based cancer therapies.
Our wider vision for the Centre is to achieve Major Cancer Research UK Centre status. This will entail establishing a true partnership with Cancer Research UK to accelerate translational research by engaging the breadth of research across UCLH and partner hospitals, and to articulate a shared vision with Cancer Research UK for philanthropy and enterprise.
Our strategy for the current triennium is to develop further the research strengths of the UCL Cancer Institute.
A critical aim is to develop strong research collaborations with other Centres. As part of the London Cancer realm, the UCL Cancer Institute is well placed to formalise interactions and make further connections with Institutions including QMUL, Crick, ICR and King’s. We are uniquely positioned to bring together the multidisciplinary science of UCL/Crick with the clinical referral base of UCL Partners/London Cancer, an integrated healthcare system serving a patient population of 3.5 million in 17 partner hospitals. To deliver this future we will develop a Centre for Cancer Evolution and a Centre for Precision and Integrative Cancer Medicine. These centres will capitalise on the breadth of world-leading research at UCL and the Crick and will deliver national leadership on translational cancer research.
The Centre will also develop multi-disciplinary interactions with other faculties and networks at UCL including Physics, Engineering, Mathematics, Neuroscience and Immunology.
We have established strong national collaborations to enhance our translational research capabilities including our joint Lung Cancer Centre of Excellence with Manchester, CCIC17 with Guys/Kings/St Thomas’s Medical School and clinical portfolio with Barts/Queen Mary’s College. Our international links with Yale and Sarah Cannon will greatly strengthen our ability to have a major impact in the fight against cancer.
Through the CRUK- funded clinical and non-clinical PhD studentship programme, the Centre will support the next generation of cancer researchers through their academic and clinical careers.
The Centre will develop a clear research engagement strategy to raise the profile of cancer research within the UCL Cancer Institute, London and nationwide.